SNY Stock Analysis: Buy, Sell, or Hold?
SNY - Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
$39.92
-0.75 (-1.84%)
▼
5d:
-2.89%
30d:
-10.23%
90d:
-6.31%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 30, 2026
26d
Get Alerted When SNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SNY shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SNY shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$61.70
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$38.31
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNY is currently trading at $39.92, which is considered oversold relative to its 30-day fair value range of $41.36 to $44.60. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.4) compared to its historical average (8.6). Remarkably, the market is currently pricing in an annual earnings decline of 4.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SNY is showing sideways momentum. The price is currently testing key support at $39.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNY scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $53.72 (+34.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNY is showing sideways momentum. The price is currently testing key support at $39.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNY scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $53.72 (+34.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$41.36 -
$44.60
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (16/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.6% below Wall St target ($53.72)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$41.36 -
$44.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$39.50
Resistance Level
$42.78
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.39
Wall Street Target
$53.72
(+34.6%)
Revenue Growth (YoY)
14.6%
Earnings Growth (YoY)
-91.2%
Profit Margin
8.1%
Valuation Discount vs History
-4.7% cheaper
PE vs Historical
7.4 vs 8.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.7%
(market-implied from PE analysis)
1-Year Target
$38.04
(-5%)
2-Year Target
$36.26
(-9%)
3-Year Target
$34.55
(-13%)
3-Yr Target (if PE normalizes)
(PE: 7→9)
$40.20
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 7.7%)
$137.53
(+245%)
Base:
(SPY PE: 7.4, Growth: 7.7%)
$49.83
(+25%)
Bear:
(PE: 6.3, Growth: 7.7%)
$42.36
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 22.22 | Current EPS (TTM): $1.83
Bull Case
$89.47
(+124%)
Analyst growth 100.0%, PE expands to 24.5
Base Case
$81.34
(+104%)
Market implied 100.0%, PE stable at 22.2
Bear Case
$27.66
(-31%)
Severe decline -20.0%, PE contracts to 18.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.4 to 8.6
Stabilization Target:
$46.45
(+16.4%)
PE Expansion Potential:
+16.4%
Share & Embed Analysis
Last updated: October 03, 2026 1:12 PM ET
Data refreshes hourly during market hours. Next update: 2:12 PM
Data refreshes hourly during market hours. Next update: 2:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1325 | 48 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$159 | 46 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$279 | 57 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$389 | 55 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$238 | 48 HOLD |
